Drug-eluting stents better than bare-metal stents for heart attack patients

Sep 25, 2009

Late-breaking data from the landmark HORIZONS-AMI clinical trial, presented at the 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, demonstrated that after two years, in heart attack patients, the use of a drug-eluting stent (paclitaxel) was safer and more effective than a bare-metal stent; and that the administration of the anticoagulant medication bivalirudin enhanced safety and efficacy compared to the use of heparin + GPIIb/IIIa inhibitors.

Results from "Two-Year Follow-up from a Prospective, Randomized Trial of Plus Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin and Paclitaxel-Eluting vs. Bare Stents in STEMI" will be presented at TCT on Friday, September 25.

"The results at two years are more impressive than both the initial 30-day and the one year results that we reported at TCT last year," said Gregg W. Stone, MD, immediate past chairman of CRF, professor of medicine at Columbia University Hospital and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital/Columbia University Medical Center. Dr. Stone is the principal investigator of the HORIZONS-AMI trial.

"The data show that use of bivalirudin alone, as opposed to a combination of heparin and GP IIb/IIIa inhibitors can save lives."

After two years, treatment with bivalirudin alone compared to heparin plus GPIIB/IIIa inhibitors resulted in:

  • A significant 36 percent reduction in major bleeding and a significant 25 percent reduction in reinfarction, with comparable rates of stent thrombosis, TVR and stroke.
  • A significant 41 percent reduction in cardiac mortality and a 25 percent reduction in all-cause mortality, the latter representing 15 lives saved per 1,000 patients treated.
In addition, at two years, the implantation of a paclitaxel-eluting stent compared to a bare-metal stent resulted in:
  • Significant 42 percent and 34 percent reductions in ischemic target lesion revascularization (TLR) and target vessel revascularization (TVR) respectively, with no evidence of late catch-up
  • Comparable rates of all-cause and cardiac mortality, reinfarction and stent thrombosis, with no safety concerns apparent
While previous studies of drug-eluting stents have often focused on their use in patients with stable or unstable chest pain, this is the largest study to focus on the appropriate use of anticoagulation medications and drug-eluting stents in patients experiencing the most dangerous form of (ST-elevation myocardial infarction).

Source: Cardiovascular Research Foundation

Explore further: Surrogate offers clues into man with 16 babies

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Surrogate offers clues into man with 16 babies

6 hours ago

When the young Thai woman saw an online ad seeking surrogate mothers, it seemed like a life-altering deal: $10,000 to help a foreign couple that wanted a child but couldn't conceive.

Nurses go on strike in Ebola-hit Liberia

6 hours ago

Nurses at Liberia's largest hospital went on strike on Monday, demanding better pay and equipment to protect them against a deadly Ebola epidemic which has killed hundreds in the west African nation.

ALS Ice Bucket Challenge arrives in North Korea

Aug 31, 2014

It's pretty hard to find a novel way to do the ALS Ice Bucket Challenge by now, but two-time Grammy-winning rapper Pras Michel, a founding member of the Fugees, has done it—getting his dousing in the center ...

Cold cash just keeps washing in from ALS challenge

Aug 28, 2014

In the couple of hours it took an official from the ALS Association to return a reporter's call for comment, the group's ubiquitous "ice bucket challenge" had brought in a few million more dollars.

Medtronic spends $350M on another European deal

Aug 27, 2014

U.S. medical device maker Medtronic is building stronger ties to Europe, a couple months after announcing a $42.9 billion acquisition that involves moving its main executive offices across the Atlantic, where it can get a ...

User comments : 0